FGFR3 and urothelial carcinoma: Patients with histologically proven urothelial carcinoma whose tumors were FGFR-1 or FGFR-3 positive and who had received at least one course of platinum-based chemotherapy in the past and whose disease had progressed were enrolled in the study [66].